Filing Analysis
Surrozen, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a placeholder for the press release containing the company's latest operational and financial performance data.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Surrozen, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 13, 2026. Stockholders elected two Class II directors, ratified the company's independent auditor, and approved executive compensation on an advisory basis.
📋 Key Facts
- The 2026 Annual Meeting was held on May 13, 2026, with 7,744,669 shares represented out of 11,486,707 total shares entitled to vote.
- Mace Rothenberg, M.D. and David J. Woodhouse, Ph.D. were elected as Class II directors to serve until the 2029 Annual Meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 7,744,358 votes in favor.
- Stockholders approved the compensation of named executive officers and voted for an annual (1-year) frequency for future advisory votes on executive compensation.
Surrozen, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release and filed under Item 2.02 of Form 8-K.
📋 Key Facts
- The report covers the fiscal quarter ended March 31, 2026.
- The filing was triggered by a press release issued on May 6, 2026.
- The company's redeemable warrants (SRZNW) are each exercisable for 'one-fifteenth of a share of Common Stock'.
- The financial information provided in Item 2.02 is furnished and not deemed 'filed' for regulatory liability purposes.
Surrozen, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 23, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The filing was signed by Andrew Maleki, Chief Financial Officer.
Surrozen, Inc. announced the resignation of Shao-Lee Lin, M.D., Ph.D. from its Board of Directors, effective January 26, 2026.
📋 Key Facts
- Shao-Lee Lin, M.D., Ph.D. resigned from the Board of Directors on January 26, 2026.
- The resignation was effective immediately.
- The company explicitly stated that the resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Surrozen, Inc. announced the appointment of Andrew Maleki as new Chief Financial Officer, effective November 12, 2025, and the transition of Charles Williams from CFO to COO/Secretary. The company also released its financial results for the quarter ended September 30, 2025.
🚩 Red Flags
- Executive turnover: The CFO is transitioning to a COO role while a new CFO is brought in, which can sometimes indicate internal restructuring or shifts in strategic focus.
📋 Key Facts
- Andrew Maleki appointed as Chief Financial Officer, effective November 12, 2025.
- Maleki's compensation includes a $385,000 base salary and a 40% annual bonus target starting in 2026.
- Maleki granted 50,000 non-statutory stock options with a 1-year cliff vesting period.
- Charles Williams is stepping down as CFO but will remain as Chief Operating Officer and Secretary.
- Company released Q3 2025 financial results (quarter ended Sept 30, 2025) via press release.
Surrozen, Inc. announced the termination of a Collaboration Agreement with TCGFB, Inc., effective November 13, 2025. The agreement was previously identified as a related-party transaction involving entities affiliated with The Column Group.
🚩 Red Flags
- Loss of potential revenue stream ($6.0 million aggregate value).
- Related-party transaction termination: The counterparty is closely linked to the company's board and major shareholders.
- Termination for convenience by a related party often signals strategic shifts or dissatisfaction that may not be fully disclosed.
📋 Key Facts
- TCGFB, Inc. terminated the Collaboration Agreement for convenience on October 14, 2025.
- The termination is effective November 13, 2025.
- No termination penalties will be incurred by either party.
- Under the original agreement, TCGFB was to pay up to $6.0 million in aggregate plus third-party costs.
- TCGFB issued warrants to Surrozen exercisable for up to 3.4 million shares of TCGFB common stock at $0.0001 per share (subject to vesting).
- The agreement was a related-party transaction: entities affiliated with The Column Group hold >5% of Surrozen, and Dr. Kutzkey (Surrozen Board Member) is Managing Partner of The Column Group.
Surrozen, Inc. entered into a sales agreement with TD Securities (USA) LLC to facilitate the potential sale of up to $50.0 million in common stock via an 'at-the-market' (ATM) offering.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
📋 Key Facts
- Entered into a Sales Agreement with TD Cowen on August 29, 2025.
- Aggregate offering amount: up to $50.0 million of Common Stock.
- The offering will be conducted as an 'at the market' (ATM) offering under Rule 415(a)(4).
- TD Cowen will receive a commission of up to 3.0% of gross sales proceeds.
- Issuance is pursuant to a previously filed Form S-3 registration statement (File No. 333-287434).
Surrozen, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release rather than disclosing new material agreements or structural changes.
📋 Key Facts
- Report date: August 08, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Company is an emerging growth company.
Surrozen, Inc. held its 2025 Annual Meeting of Stockholders on May 14, 2025. The meeting resulted in the successful election of three Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on May 14, 2025.
- Three nominees (Anna Berkenblit, M.D., Eric Bjerkholt, and Tim Kutzkey, Ph.D.) were elected to the Board of Directors for Class I until 2028.
- Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Total shares entitled to vote: 3,281,169; Shares represented at meeting: 2,308,787.
Surrozen, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: May 9, 2025
- Reporting period: Quarter ended March 31, 2025
- The company is an emerging growth company
- Financial results were released via Exhibit 99.1
Surrozen, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of year-end earnings via a press release.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) containing financial results.
- The filing is under Item 2.02 (Results of Operations and Financial Condition).
Surrozen, Inc. announced a significant two-tranche private placement totaling approximately $175 million in potential gross proceeds, contingent on FDA milestones for its SZN-8141 program. The deal includes the issuance of common stock, pre-funded warrants, and Series E Common Warrants.
🚩 Red Flags
- Significant dilution potential from large tranches of warrants and pre-funded warrants.
- Contingent funding: The second $98.6M tranche is tied to a specific FDA milestone (SZN-8141 IND clearance).
- Related-party transaction: Dr. Tim Kutzkey, newly appointed director, is a Managing Partner of The Column Group, which has a research collaboration with the company and holds >5% of common stock.
- Amendment of prior warrants: Significant reduction in exercise prices for Series A and B warrants (e.g., from $15.50 to $11.54) suggests downward pressure on share value or restructuring.
📋 Key Facts
- First Tranche: 6,586,415 Units closed on March 26, 2025, for ~$76.4 million gross proceeds.
- Second Tranche: 8,499,821 Units committed at $11.60 per unit, totaling ~$98.6 million gross proceeds.
- The Second Closing is contingent upon FDA clearance of the SZN-8141 Investigational New Drug Application by October 31, 2026.
- Pre-Funded Warrants have an exercise price of $0.0001 per share and are exercisable immediately.
- Series E Common Warrants have an exercise price of $11.54 and expire in five years.
- The company will file a registration statement for the resale of these securities within 30-90 days.
Surrozen, Inc. filed an 8-K to furnish a press release and corporate presentation under Item 7.01 (Regulation FD Disclosure). The filing does not contain substantive financial news or material agreements within the text provided.
📋 Key Facts
- Filed on March 24, 2025
- The company released a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2)
- Information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 of the Exchange Act
- Company is an emerging growth company
Surrozen, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release via press release.
📋 Key Facts
- The company issued a press release on November 6, 2024, regarding quarterly financial results.
- Reporting period: Quarter ended September 30, 2024.
- The filing includes Exhibit 99.1 containing the press release.
Surrozen, Inc. entered into a lease amendment to extend its headquarters lease in South San Francisco for an additional 48 months. The extension begins May 1, 2025, and runs through April 30, 2029.
🚩 Red Flags
- Increased fixed operating expense (rent escalation from $2.3M to $2.6M).
📋 Key Facts
- Lease term extended by 48 months starting May 1, 2025, expiring April 30, 2029.
- Annual base rent escalates from $2.3 million to $2.6 million over the extension period.
- Includes a one-time option to terminate the lease by paying a $400,000 fee on or before December 31, 2025.
Surrozen, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes an exhibit (99.1) containing the press release of financial results.
- Company is classified as an emerging growth company.
Surrozen, Inc. announced the resignation of Tim Kutzkey, Ph.D. from the company's Board of Directors and all associated committees, effective June 30, 2024.
📋 Key Facts
- Tim Kutzkey, Ph.D. resigned as a member of the Board of Directors on June 30, 2024.
- Resignation includes departure from all board committees.
- The company explicitly stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Surrozen, Inc. held its 2024 Annual Meeting of Stockholders on June 5, 2024. The meeting resulted in the successful election of three Class III directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on June 5, 2024.
- Three nominees (Christopher Y. Chai, Mary Haak-Frendscho, Ph.D., and Craig Parker) were elected to the Board of Directors for Class III terms until 2027.
- Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for FY2024.
- Total shares entitled to vote: 3,198,786; Shares represented at meeting: 1,808,279.
Surrozen, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: May 08, 2024
- Reporting period: Quarter ended March 31, 2024
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Surrozen, Inc. entered into a Securities Purchase Agreement on April 1, 2024, to conduct a private placement of common stock and various series of warrants totaling approximately $17.5 million in gross proceeds. The offering is heavily tied to clinical trial milestones for the company's SZN-043 program.
🚩 Red Flags
- Significant potential dilution: The warrant structure (Series A-D) could result in the issuance of millions of additional shares if clinical milestones are met.
- Milestone-contingent warrants: The financing is highly dependent on specific clinical outcomes for SZN-043, creating binary risk for investors.
- Complex warrant structure: Multiple series of warrants with varying exercise prices ($14.25 to $16.96) and expiration triggers.
📋 Key Facts
- Private placement of 1,089,033 shares and Pre-Funded Warrants at $15.50 per share.
- Aggregate gross proceeds from the initial tranche are approximately $17.5 million.
- Issuance of four series of warrants (Series A, B, C, and D) with total potential proceeds up to ~$160 million if all milestones are met.
- Series B warrants trigger upon 15 patients in Phase 1b trial showing <30% mortality rate; Series C/D tied to final Phase 1b data and Phase 2/3 enrollment respectively.
- Management participated in the offering, purchasing 2,948 shares at $16.96 per share.
Surrozen, Inc. issued a press release and corporate presentation regarding safety, pharmacodynamic, and liver function data for its SZN-043 program. This filing is a Regulation FD disclosure of clinical/scientific data rather than a material financial event.
📋 Key Facts
- Released clinical data (safety, pharmacodynamic, and liver function) for SZN-043 on April 1, 2024.
- Issued a corporate presentation alongside the press release to provide context on the data.
- The information was furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18.
Surrozen, Inc. announced the appointment of Charles Williams to the concurrent role of Chief Operating Officer (COO), effective February 1, 2024. Mr. Williams will continue to serve in his existing capacity as Chief Financial Officer (CFO).
🚩 Red Flags
- None identified; this is a dual-role appointment for an existing executive.
📋 Key Facts
- Charles Williams appointed as Chief Operating Officer (COO) effective Feb 1, 2024.
- Mr. Williams retains his current role as Chief Financial Officer (CFO).
- Annual base salary for Mr. Williams increased to $465,000 as part of the appointment and annual compensation review.
- The appointment is an expansion of duties rather than a replacement of personnel.
Surrozen, Inc. announced the discontinuation of its SZN-1326 program for inflammatory bowel disease (IBD) due to safety concerns and strategic considerations. Additionally, the company provided updates on its SZN-043 clinical trial enrollment.
🚩 Red Flags
- Pipeline setback: Discontinuation of a drug candidate (SZN-1326).
- Safety signal: Grade 3 ALT and AST elevations observed in clinical subjects.
- Strategic pivot/resource reallocation due to 'significant clinical development expenses'.
📋 Key Facts
- Discontinuation of SZN-1326 development in IBD following Phase 1 single ascending dose trials.
- SZN-1326 study reported asymptomatic liver transaminase elevations (Grade 3 ALT and AST) in four subjects at higher doses.
- Enrollment for SZN-043 Phase 1a clinical trial is complete; safety/pharmacodynamic data expected in Q1 2024.
- Phase 1b enrollment for SZN-043 (alcohol-associated hepatitis) to begin soon, with potential proof-of-concept data in H2 2024.